Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,599 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Turner's Syndrome
Interventions: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 138 Months to 13 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Heart Failure
Interventions: Non-invasive hemodynamic monitoring (CVInsight™ [CVI]); Device
Lead sponsor: Intelomed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions: Capsaicin Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 8
States / cities: Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more

Conditions: Breast Cancer, Hyperglycemia
Interventions: FreeStyle Libre Pro; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Irritation
Interventions: Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%; Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Le Fort, Pain, Postoperative
Interventions: Standardized Anesthetic Course from Premedication to Induction; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%, Vehicle Cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 3 Months to 23 Months
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Birmingham, Alabama • Bryant, Arkansas • Los Angeles, California + 32 more

Conditions: Nicotine Dependence, Tobacco Use
Interventions: Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain; Drug · Behavioral
Lead sponsor: Mark Vander Weg; Other
Eligibility: 18 Years to 99 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Migraine Disorders
Interventions: NP101; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more

Conditions: Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions: Not listed
Lead sponsor: Tina Baykaner; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Duarte, California • San Diego, California • Stanford, California

Conditions: Multiple Sclerosis
Interventions: Anesthetic Topical Adhesive Synera; Drug
Lead sponsor: Brown, Theodore R., M.D., MPH; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Amblyopia
Interventions: Atropine, Eye Patch; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Aging
Interventions: Nicotine patch, oral mecamylamine, placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Amblyopia
Interventions: Eye patch, spectacles, atropine; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions: Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel; Drug
Lead sponsor: Naval Aeromedical Research Unit, Dayton; Federal
Eligibility: 18 Years to 59 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Arthroplasty, Replacement, Knee
Interventions: Radiofrequency Ablation (RFA), Simulated Radiofrequency Ablation (RFA); Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fertility, Contraception
Interventions: Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Turner Syndrome, Primary Ovarian Insufficiency
Interventions: Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 12 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Delirium
Interventions: Clonidine, Placebo; Drug
Lead sponsor: Memorial Health University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Erythema
Interventions: MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Allergic Sensitization
Interventions: Light Therapy Mask Cream; Device
Lead sponsor: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Pain, Postoperative
Interventions: Transdermal Lidocaine Patch, Transdermal Hydrocolloid Placebo Patch; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Drug Addiction, Smoking Cessation
Interventions: Nicotine transdermal system, Nicotine containing cigarette, Placebo cigarette; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Search by objective public record fields.

Initiating Transdermal Estradiol Therapy in Turner's Syndrome

Correlating Noninvasive Cardiovascular Measures to Left Ventricular End Diastolic Pressure in Heart Failure

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

Glucose Monitoring During Chemotherapy

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

Anesthetic Optimization in Pediatric LeFort Surgeries

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy

Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

The Nicotinic Cholinergic System and Cognitive Aging

An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes

Regulation of Cervical Mucus Secretion

Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome

Use of Transdermal Clonidine in Trauma Patients

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100

The OBstetric Lidocaine Patch (OBLido) Trial

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females